Assembly Biosciences (ASMB)
NASDAQ:ASMB
Want to see ASMB full AI Analyst Report?
Top Page
Assembly Biosciences
(NASDAQ:ASMB)
Select Model
Select Model
Rating:45Neutral
Price Target:
$23.50
▼(-19.63% Downside)
Action:Reiterated
Date:06/06/26
The score is held down primarily by weak cash flow (sizable ongoing burn) and a bearish technical setup (price below key moving averages with negative MACD). These are partially offset by a strong, low-debt balance sheet and the recent capital raise and pipeline expansion, which improve funding capacity and strategic optionality despite dilution.
Positive Factors
Low leverage / strong balance sheet
Extremely low leverage and large equity provide durable financial flexibility for a clinical-stage biotech. This reduces solvency risk, supports ongoing R&D spending without immediate debt pressure, and allows management to pursue trial timelines or partnerships without urgent refinancing needs.
Negative Factors
Sustained cash burn
Consistent negative operating and free cash flow near -$40M TTM indicates the company is burning cash to fund operations and trials. Unless offset by recurring funding, this creates a persistent need for capital raises that can pressure timelines and stakeholder returns over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Extremely low leverage and large equity provide durable financial flexibility for a clinical-stage biotech. This reduces solvency risk, supports ongoing R&D spending without immediate debt pressure, and allows management to pursue trial timelines or partnerships without urgent refinancing needs.
Read all positive factors
Assembly Biosciences (ASMB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$446.48M
Dividend YieldN/A
Average Volume (3M)164.41K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth121.11%
EPS Growth80.74%
CountryUS
Employees73
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding19,817,250
10 Day Avg. Volume178,321
30 Day Avg. Volume164,409
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue5.78
Enterprise Value/Gross Profit7.48
Enterprise Value/Ebitda-65.64
Forecast
1Y Price Target
$44.33Price Target Upside51.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.68
Revenue Forecast (FY)$57.96M
Assembly Biosciences Business Overview & Revenue Model
Company Description
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candida...
How the Company Makes Money
null...
Assembly Biosciences Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 71.10M | 72.30M | 28.52M | 7.16M | 0.00 | 6.25M |
| Gross Profit | 54.91M | 72.17M | 28.52M | -41.74M | -69.08M | 6.25M |
| EBITDA | -6.26M | -5.99M | -39.72M | -60.74M | -92.52M | -90.58M |
| Net Income | -6.38M | -6.12M | -40.18M | -61.23M | -93.09M | -129.85M |
Balance Sheet | ||||||
| Total Assets | 235.51M | 257.59M | 119.17M | 136.82M | 101.79M | 191.06M |
| Cash, Cash Equivalents and Short-Term Investments | 226.60M | 248.11M | 112.08M | 130.25M | 91.61M | 146.63M |
| Total Debt | 2.49M | 2.63M | 3.09M | 2.34M | 3.46M | 6.48M |
| Total Liabilities | 36.90M | 50.84M | 85.81M | 95.73M | 19.13M | 22.13M |
| Stockholders Equity | 198.61M | 206.75M | 33.36M | 41.10M | 82.66M | 168.93M |
Cash Flow | ||||||
| Free Cash Flow | -39.84M | -41.16M | -51.15M | 22.49M | -84.56M | -96.49M |
| Operating Cash Flow | -39.75M | -41.09M | -51.12M | 22.74M | -84.46M | -93.40M |
| Investing Cash Flow | -125.44M | -113.47M | 40.17M | -69.14M | 90.64M | 26.52M |
| Financing Cash Flow | 172.89M | 174.67M | 29.45M | 13.82M | 614.00K | 53.06M |
Assembly Biosciences Technical Analysis
Negative
29.24
Price Trends
27.60
Negative
27.78
Negative
28.91
Negative
Market Momentum
-1.61
Positive
34.41
Neutral
11.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Negative. The current price of 29.24 is above the 20-day moving average (MA) of 25.56, above the 50-day MA of 27.60, and above the 200-day MA of 28.91, indicating a bearish trend. The MACD of -1.61 indicates Positive momentum. The RSI at 34.41 is Neutral, neither overbought nor oversold. The STOCH value of 11.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ASMB.
Assembly Biosciences Risk Analysis
Assembly Biosciences disclosed 30 risk factors in its most recent earnings report. Assembly Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Assembly Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $211.88M | -1.97 | -47.35% | ― | -46.21% | 23.81% | |
47 Neutral | $329.79M | -4.05 | -47.48% | ― | ― | 56.00% | |
46 Neutral | $763.48M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
45 Neutral | $446.48M | -60.79 | -4.21% | ― | 121.11% | 80.74% | |
44 Neutral | $379.62M | -11.29 | -34.82% | ― | ― | 41.21% | |
44 Neutral | $770.06M | -4.66 | -101.19% | ― | ― | -3.74% |
* Healthcare Sector Average
ASMB
Assembly Biosciences
22.96
6.11
36.26%
BNTC
Benitec Biopharma
11.18
-5.30
-32.16%
ANNX
Annexon Biosciences
4.71
2.22
89.16%
QSI
Quantum-Si
0.95
-0.71
-43.01%
VOR
Vor Biopharma
14.36
10.72
294.51%
LXEO
Lexeo Therapeutics, Inc.
4.37
0.43
10.91%
Assembly Biosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Assembly Biosciences Expands Equity Plans, Reelects Board
Positive
Jun 5, 2026
At its annual meeting of stockholders on June 4, 2026, Assembly Biosciences, Inc. secured shareholder approval to expand its equity compensation programs, increasing the share reserve under its Amended and Restated 2018 Stock Incentive Plan from 1...
Business Operations and StrategyPrivate Placements and Financing
Assembly Biosciences Completes Significant Equity Offering Financing
Positive
May 26, 2026
On May 21, 2026, Assembly Biosciences entered an underwriting agreement for an underwritten, registered offering of 3,358,602 common shares at $26.50 and pre-funded warrants for up to 415,000 shares at $26.499, with the underwriters exercising a 3...
Business Operations and StrategyProduct-Related Announcements
Assembly Biosciences Expands ABI-6250 Liver Disease Program
Positive
May 22, 2026
On May 22, 2026, Assembly Biosciences announced that it will expand clinical development of its oral NTCP inhibitor candidate ABI-6250, originally aimed at chronic hepatitis delta virus infection, into primary biliary cholangitis and primary scler...
Business Operations and StrategyExecutive/Board Changes
Assembly Biosciences Adopts 2026 Performance-Based Bonus Plan
Positive
Mar 30, 2026
On March 24, 2026, Assembly Biosciences’ board compensation committee approved a new 2026 Corporate Bonus Plan, effective January 1, 2026, establishing a performance-based cash incentive structure for employees based on a mix of company-wide...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.